The Maryland-based company Novavax has developed a protein-based coronavirus vaccine called NVX-CoV2373. The vaccine produced strikingly high levels of antibodies in early clinical trials. In September, the vaccine entered a Phase 3 clinical trial in the United Kingdom, and another one in the United States at the end of December. Those trials will show whether the vaccine is safe and effective.
Coronavirus Proteins
The SARS-CoV-2 virus is studded with proteins that it uses to enter human cells. These so-called spike proteins make a tempting target for potential vaccines and treatments.Read more:
https://www.nytimes.com/interactive/2020/health/novavax-covid-19-vaccine.html?smid=tw-nytimesscience&smtyp=cur
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου